{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T08:38:53Z","timestamp":1789720733120,"version":"4.0.1"},"reference-count":186,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2016,1,4]],"date-time":"2016-01-04T00:00:00Z","timestamp":1451865600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2016,1,4]],"date-time":"2016-01-04T00:00:00Z","timestamp":1451865600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100000048","name":"American Cancer Society","doi-asserted-by":"publisher","award":["RSG-14-218-01-TBG"],"award-info":[{"award-number":["RSG-14-218-01-TBG"]}],"id":[{"id":"10.13039\/100000048","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000892","name":"Prostate Cancer Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000892","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006293","name":"American Society of Clinical Oncology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006293","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["P30CA125123"],"award-info":[{"award-number":["P30CA125123"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["HORM CANC"],"published-print":{"date-parts":[[2016,4]]},"DOI":"10.1007\/s12672-015-0239-9","type":"journal-article","created":{"date-parts":[[2016,1,4]],"date-time":"2016-01-04T14:49:48Z","timestamp":1451918988000},"page":"84-103","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":51,"title":["Moving Beyond the Androgen Receptor (AR): Targeting AR-Interacting Proteins to Treat Prostate Cancer"],"prefix":"10.1007","volume":"7","author":[{"given":"Christopher","family":"Foley","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas","family":"Mitsiades","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,1,4]]},"reference":[{"issue":"5","key":"239_CR1","doi-asserted-by":"publisher","first-page":"E359","DOI":"10.1002\/ijc.29210","volume":"136","author":"J Ferlay","year":"2015","unstructured":"Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray F (2015) Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 136(5):E359\u201386. doi:10.1002\/ijc.29210","journal-title":"Int J Cancer"},{"key":"239_CR2","first-page":"1","volume":"2014","author":"AC Society","year":"2014","unstructured":"Society AC (2014) Cancer facts & figures. Am Cancer Soc 2014:1\u201372","journal-title":"Am Cancer Soc"},{"key":"239_CR3","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21254\/pdf","author":"RL Siegel","year":"2015","unstructured":"Siegel RL, Miller KD, Jemal A (2015) Cancer statistics, 2015 - Siegel - 2015 - CA: a Cancer Journal for Clinicians - Wiley Online Library. Cancer J Clin. doi:10.3322\/caac.21254\/pdf","journal-title":"Cancer J Clin"},{"key":"239_CR4","unstructured":"Huggins C, Hodges CV (1941) Studies on prostatic cancer: I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. 1941:9\u201312"},{"issue":"15","key":"239_CR5","doi-asserted-by":"publisher","first-page":"4599","DOI":"10.1158\/0008-5472.CAN-12-4414","volume":"73","author":"N Mitsiades","year":"2013","unstructured":"Mitsiades N (2013) A road map to comprehensive androgen receptor axis targeting for castration-resistant prostate cancer. Cancer Res 73(15):4599\u20134605. doi:10.1158\/0008-5472.CAN-12-4414","journal-title":"Cancer Res"},{"issue":"2","key":"239_CR6","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.1210\/endo-126-2-1165","volume":"126","author":"PB Grino","year":"1990","unstructured":"Grino PB, Griffin JE, Wilson JD (1990) Testosterone at high concentrations interacts with the human androgen receptor similarly to dihydrotestosterone. Endocrinology 126(2):1165\u20131172. doi:10.1210\/endo-126-2-1165","journal-title":"Endocrinology"},{"issue":"23","key":"239_CR7","doi-asserted-by":"publisher","first-page":"6142","DOI":"10.1158\/0008-5472.CAN-12-1335","volume":"72","author":"N Mitsiades","year":"2012","unstructured":"Mitsiades N, Sung CC, Schultz N, Danila DC, He B, Eedunuri VK, Fleisher M, Sander C, Sawyers CL, Scher HI (2012) Distinct patterns of dysregulated expression of enzymes involved in androgen synthesis and metabolism in metastatic prostate cancer tumors. Cancer Res 72(23):6142\u20136152. doi:10.1158\/0008-5472.CAN-12-1335","journal-title":"Cancer Res"},{"issue":"4","key":"239_CR8","doi-asserted-by":"publisher","first-page":"1391","DOI":"10.3892\/ol.2014.2388","volume":"8","author":"JM Lacy","year":"2014","unstructured":"Lacy JM, Kyprianou N (2014) A tale of two trials: the impact of 5\u03b1-reductase inhibition on prostate cancer (Review). Oncol Lett 8(4):1391\u20131396. doi:10.3892\/ol.2014.2388","journal-title":"Oncol Lett"},{"issue":"3","key":"239_CR9","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1056\/NEJMoa030660","volume":"349","author":"IM Thompson","year":"2003","unstructured":"Thompson IM, Goodman PJ, Tangen CM, Lucia MS, Miller GJ, Ford LG, Lieber MM, Cespedes RD, Atkins JN, Lippman SM, Carlin SM, Ryan A, Szczepanek CM, Crowley JJ, Coltman CA (2003) The influence of finasteride on the development of prostate cancer. N Engl J Med 349(3):215\u2013224. doi:10.1056\/NEJMoa030660","journal-title":"N Engl J Med"},{"issue":"13","key":"239_CR10","doi-asserted-by":"publisher","first-page":"1192","DOI":"10.1056\/NEJMoa0908127","volume":"362","author":"GL Andriole","year":"2010","unstructured":"Andriole GL, Bostwick DG, Brawley OW, Gomella LG, Marberger M, Montorsi F, Pettaway CA, Tammela TL, Teloken C, Tindall DJ, Somerville MC, Wilson TH, Fowler IL, Rittmaster RS, REDUCE Study Group (2010) Effect of dutasteride on the risk of prostate cancer. N Engl J Med 362(13):1192\u20131202. doi:10.1056\/NEJMoa0908127","journal-title":"N Engl J Med"},{"issue":"7","key":"239_CR11","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1056\/NEJMoa1215932","volume":"369","author":"IM Thompson Jr","year":"2013","unstructured":"Thompson IM Jr, Goodman PJ, Tangen CM, Parnes HL, Minasian LM, Godley PA, Lucia MS, Ford LG (2013) Long-term survival of participants in the prostate cancer prevention trial. N Engl J Med 369(7):603\u2013610. doi:10.1056\/NEJMoa1215932","journal-title":"N Engl J Med"},{"issue":"2","key":"239_CR12","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1210\/er.2002-0032","volume":"25","author":"CA Heinlein","year":"2004","unstructured":"Heinlein CA, Chang C (2004) Androgen receptor in prostate cancer. Endocr Rev 25(2):276\u2013308. doi:10.1210\/er.2002-0032","journal-title":"Endocr Rev"},{"issue":"1","key":"239_CR13","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/0303-7207(96)03819-1","volume":"120","author":"CM Wilson","year":"1996","unstructured":"Wilson CM, McPhaul MJ (1996) A and B forms of the androgen receptor are expressed in a variety of human tissues. Mol Cell Endocrinol 120(1):51\u201357","journal-title":"Mol Cell Endocrinol"},{"issue":"3","key":"239_CR14","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1677\/jme.0.0270309","volume":"27","author":"CW Gregory","year":"2001","unstructured":"Gregory CW, He B, Wilson EM (2001) The putative androgen receptor\u2014a form results from in vitro proteolysis. J Mol Endocrinol 27(3):309\u2013319","journal-title":"J Mol Endocrinol"},{"issue":"1","key":"239_CR15","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1158\/0008-5472.CAN-08-2764","volume":"69","author":"R Hu","year":"2009","unstructured":"Hu R, Dunn TA, Wei S, Isharwal S, Veltri RW, Humphreys E, Han M, Partin AW, Vessella RL, Isaacs WB, Bova GS, Luo J (2009) Ligand-independent androgen receptor variants derived from splicing of cryptic exons signify hormone-refractory prostate cancer. Cancer Res 69(1):16\u201322. doi:10.1158\/0008-5472.CAN-08-2764","journal-title":"Cancer Res"},{"issue":"13","key":"239_CR16","doi-asserted-by":"publisher","first-page":"5469","DOI":"10.1158\/0008-5472.CAN-08-0594","volume":"68","author":"SM Dehm","year":"2008","unstructured":"Dehm SM, Schmidt LJ, Heemers HV, Vessella RL, Tindall DJ (2008) Splicing of a novel androgen receptor exon generates a constitutively active androgen receptor that mediates prostate cancer therapy resistance. Cancer Res 68(13):5469\u20135477. doi:10.1158\/0008-5472.CAN-08-0594","journal-title":"Cancer Res"},{"issue":"6","key":"239_CR17","doi-asserted-by":"publisher","first-page":"2108","DOI":"10.1158\/0008-5472.CAN-10-1998","volume":"71","author":"Y Li","year":"2011","unstructured":"Li Y, Alsagabi M, Fan D, Bova GS, Tewfik AH, Dehm SM (2011) Intragenic rearrangement and altered RNA splicing of the androgen receptor in a cell-based model of prostate cancer progression. Cancer Res 71(6):2108\u20132117. doi:10.1158\/0008-5472.CAN-10-1998","journal-title":"Cancer Res"},{"issue":"22","key":"239_CR18","first-page":"6606","volume":"62","author":"CG Tepper","year":"2002","unstructured":"Tepper CG, Boucher DL, Ryan PE, Ma A-H, Xia L, Lee L-F, Pretlow TG, Kung H-J (2002) Characterization of a novel androgen receptor mutation in a relapsed CWR22 prostate cancer xenograft and cell line. Cancer Res 62(22):6606\u20136614","journal-title":"Cancer Res"},{"issue":"9","key":"239_CR19","doi-asserted-by":"publisher","first-page":"4334","DOI":"10.1210\/en.2007-0446","volume":"148","author":"M Jagla","year":"2007","unstructured":"Jagla M, F\u00e8ve M, Kessler P, Lapouge G, Erdmann E, Serra S, Bergerat J-P, C\u00e9raline J (2007) A splicing variant of the androgen receptor detected in a metastatic prostate cancer exhibits exclusively cytoplasmic actions. Endocrinology 148(9):4334\u20134343. doi:10.1210\/en.2007-0446","journal-title":"Endocrinology"},{"issue":"1","key":"239_CR20","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1111\/j.1432-1033.2004.04395.x","volume":"272","author":"I Ahrens-Fath","year":"2005","unstructured":"Ahrens-Fath I, Politz O, Geserick C, Haendler B (2005) Androgen receptor function is modulated by the tissue-specific AR45 variant. FEBS J 272(1):74\u201384. doi:10.1111\/j.1742-4658.2004.04395.x","journal-title":"FEBS J"},{"issue":"39","key":"239_CR21","doi-asserted-by":"publisher","first-page":"16759","DOI":"10.1073\/pnas.1012443107","volume":"107","author":"PA Watson","year":"2010","unstructured":"Watson PA, Chen YF, Balbas MD, Wongvipat J, Socci ND, Viale A, Kim K, Sawyers CL (2010) Constitutively active androgen receptor splice variants expressed in castration-resistant prostate cancer require full-length androgen receptor. Proc Natl Acad Sci U S A 107(39):16759\u201316765. doi:10.1073\/pnas.1012443107","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"18","key":"239_CR22","doi-asserted-by":"publisher","first-page":"6019","DOI":"10.1158\/0008-5472.CAN-11-1417","volume":"71","author":"MS Darshan","year":"2011","unstructured":"Darshan MS, Loftus MS, Thadani-Mulero M, Levy BP, Escuin D, Zhou XK, Gjyrezi A, Chanel-Vos C, Shen R, Tagawa ST, Bander NH, Nanus DM, Giannakakou P (2011) Taxane-induced blockade to nuclear accumulation of the androgen receptor predicts clinical responses in metastatic prostate cancer. Cancer Res 71(18):6019\u20136029. doi:10.1158\/0008-5472.CAN-11-1417","journal-title":"Cancer Res"},{"issue":"20","key":"239_CR23","doi-asserted-by":"publisher","first-page":"7992","DOI":"10.1158\/0008-5472.CAN-10-0585","volume":"70","author":"M-L Zhu","year":"2010","unstructured":"Zhu M-L, Horbinski CM, Garzotto M, Qian DZ, Beer TM, Kyprianou N (2010) Tubulin-targeting chemotherapy impairs androgen receptor activity in prostate cancer. Cancer Res 70(20):7992\u20138002. doi:10.1158\/0008-5472.CAN-10-0585","journal-title":"Cancer Res"},{"key":"239_CR24","doi-asserted-by":"crossref","unstructured":"Zhang G, Liu X, Li J, Ledet E, Alvarez X, Qi Y, Fu X, Sartor O, Dong Y, Zhang H (2015) Androgen receptor splice variants circumvent AR blockade by microtubule-targeting agents. Oncotarget","DOI":"10.18632\/oncotarget.4396"},{"issue":"8","key":"239_CR25","doi-asserted-by":"publisher","first-page":"2270","DOI":"10.1158\/0008-5472.CAN-13-2876","volume":"74","author":"M Thadani-Mulero","year":"2014","unstructured":"Thadani-Mulero M, Portella L, Sun S, Sung M, Matov A, Vessella RL, Corey E, Nanus DM, Plymate SR, Giannakakou P (2014) Androgen receptor splice variants determine taxane sensitivity in prostate cancer. Cancer Res 74(8):2270\u20132282. doi:10.1158\/0008-5472.CAN-13-2876","journal-title":"Cancer Res"},{"issue":"9","key":"239_CR26","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1038\/ncponc1201","volume":"5","author":"B Schurko","year":"2008","unstructured":"Schurko B, Oh WK (2008) Docetaxel chemotherapy remains the standard of care in castration-resistant prostate cancer. Nat Clin Pract Oncol 5(9):506\u2013507. doi:10.1038\/ncponc1201","journal-title":"Nat Clin Pract Oncol"},{"key":"239_CR27","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)61389-X","author":"JS de Bono","year":"2010","unstructured":"de Bono JS, Oudard S, Ozguroglu M, Hansen S (2010) Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet. doi:10.1016\/S0140-6736(10)61389-X","journal-title":"Lancet"},{"issue":"8","key":"239_CR28","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1056\/NEJMoa1503747","volume":"373","author":"CJ Sweeney","year":"2015","unstructured":"Sweeney CJ, Chen Y-H, Carducci M, Liu G, Jarrard DF, Eisenberger M, Wong Y-N, Hahn N, Kohli M, Cooney MM, Dreicer R, Vogelzang NJ, Picus J, Shevrin D, Hussain M, Garcia JA, DiPaola RS (2015) Chemohormonal therapy in metastatic hormone-sensitive prostate cancer. N Engl J Med 373(8):737\u2013746. doi:10.1056\/NEJMoa1503747","journal-title":"N Engl J Med"},{"issue":"3","key":"239_CR29","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1016\/j.molonc.2014.10.014","volume":"9","author":"SK Martin","year":"2015","unstructured":"Martin SK, Ba\u00f1uelos CA, Sadar MD, Kyprianou N (2015) N-terminal targeting of androgen receptor variant enhances response of castration resistant prostate cancer to taxane chemotherapy. Mol Oncol 9(3):628\u2013639. doi:10.1016\/j.molonc.2014.10.014","journal-title":"Mol Oncol"},{"issue":"11","key":"239_CR30","doi-asserted-by":"publisher","first-page":"4447","DOI":"10.1158\/0008-5472.CAN-08-0249","volume":"68","author":"RB Montgomery","year":"2008","unstructured":"Montgomery RB, Mostaghel EA, Vessella R, Hess DL, Kalhorn TF, Higano CS, True LD, Nelson PS (2008) Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth. Cancer Res 68(11):4447\u20134454. doi:10.1158\/0008-5472.CAN-08-0249","journal-title":"Cancer Res"},{"issue":"20","key":"239_CR31","doi-asserted-by":"publisher","first-page":"6503","DOI":"10.1158\/0008-5472.CAN-11-0532","volume":"71","author":"C Cai","year":"2011","unstructured":"Cai C, Chen S, Ng P, Bubley GJ, Nelson PS, Mostaghel EA, Marck B, Matsumoto AM, Simon NI, Wang H, Chen S, Balk SP (2011) Intratumoral de novo steroid synthesis activates androgen receptor in castration-resistant prostate cancer and is upregulated by treatment with CYP17A1 inhibitors. Cancer Res 71(20):6503\u20136513. doi:10.1158\/0008-5472.CAN-11-0532","journal-title":"Cancer Res"},{"issue":"5","key":"239_CR32","doi-asserted-by":"publisher","first-page":"1817","DOI":"10.1097\/01.ju.0000091873.09677.f4","volume":"170","author":"OH Ford III","year":"2003","unstructured":"Ford OH III, Gregory CW, Kim D, Smitherman AB, Mohler JL (2003) Androgen receptor gene amplification and protein expression in recurrent prostate cancer. J Urol 170(5):1817\u20131821. doi:10.1097\/01.ju.0000091873.09677.f4","journal-title":"J Urol"},{"issue":"4","key":"239_CR33","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1038\/ng0495-401","volume":"9","author":"T Visakorpi","year":"1995","unstructured":"Visakorpi T, Hyytinen E, Koivisto P, Tanner M, Kein\u00e4nen R, Palmberg C, Palotie A, Tammela T, Isola J, Kallioniemi OP (1995) In vivo amplification of the androgen receptor gene and progression of human prostate cancer. Nat Genet 9(4):401\u2013406. doi:10.1038\/ng0495-401","journal-title":"Nat Genet"},{"issue":"6","key":"239_CR34","first-page":"429","volume":"13","author":"G Sufrin","year":"1976","unstructured":"Sufrin G, Coffey DS (1976) Flutamide. Mechanism of action of a new nonsteroidal antiandrogen. Invest Urol 13(6):429\u2013434","journal-title":"Invest Urol"},{"issue":"1","key":"239_CR35","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/S0090-4295(96)80003-3","volume":"47","author":"BJA Furr","year":"1996","unstructured":"Furr BJA, Tucker H (1996) The preclinical development of bicalutamide: pharmacodynamics and mechanism of action. Urology 47(1):13\u201325. doi:10.1016\/S0090-4295(96)80003-3","journal-title":"Urology"},{"issue":"8","key":"239_CR36","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.1200\/JCO.1993.11.8.1566","volume":"11","author":"HI Scher","year":"1993","unstructured":"Scher HI, Kelly WK (1993) Flutamide withdrawal syndrome: its impact on clinical trials in hormone-refractory prostate cancer. J Clin Oncol 11(8):1566\u20131572","journal-title":"J Clin Oncol"},{"issue":"21","key":"239_CR37","doi-asserted-by":"publisher","first-page":"1393","DOI":"10.1056\/NEJM199505253322101","volume":"332","author":"ME Taplin","year":"1995","unstructured":"Taplin ME, Bubley GJ, Shuster TD, Frantz ME, Spooner AE, Ogata GK, Keer HN, Balk SP (1995) Mutation of the androgen-receptor gene in metastatic androgen-independent prostate cancer. N Engl J Med 332(21):1393\u20131398. doi:10.1056\/NEJM199505253322101","journal-title":"N Engl J Med"},{"issue":"11","key":"239_CR38","first-page":"4315","volume":"61","author":"CW Gregory","year":"2001","unstructured":"Gregory CW, He B, Johnson RT, Ford OH, Mohler JL, French FS, Wilson EM (2001) A mechanism for androgen receptor-mediated prostate cancer recurrence after androgen deprivation therapy. Cancer Res 61(11):4315\u20134319","journal-title":"Cancer Res"},{"issue":"17","key":"239_CR39","doi-asserted-by":"publisher","first-page":"6201","DOI":"10.1073\/pnas.0500381102","volume":"102","author":"CE Bohl","year":"2005","unstructured":"Bohl CE, Gao W, Miller DD, Bell CE, Dalton JT (2005) Structural basis for antagonism and resistance of bicalutamide in prostate cancer. Proc Natl Acad Sci 102(17):6201\u20136206. doi:10.1073\/pnas.0500381102","journal-title":"Proc Natl Acad Sci"},{"issue":"1","key":"239_CR40","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1038\/nm972","volume":"10","author":"CD Chen","year":"2004","unstructured":"Chen CD, Welsbie DS, Tran C, Baek SH, Chen R, Vessella R, Rosenfeld MG, Sawyers CL (2004) Molecular determinants of resistance to antiandrogen therapy. Nat Med 10(1):33\u201339. doi:10.1038\/nm972","journal-title":"Nat Med"},{"issue":"12","key":"239_CR41","doi-asserted-by":"publisher","first-page":"2317","DOI":"10.1038\/sj.bjc.6601879","volume":"90","author":"A O\u2019Donnell","year":"2004","unstructured":"O\u2019Donnell A, Judson I, Dowsett M, Raynaud F, Dearnaley D, Mason M, Harland S, Robbins A, Halbert G, Nutley B, Jarman M (2004) Hormonal impact of the 17|[alpha]|-hydroxylase|[sol]|C17,20-lyase inhibitor abiraterone acetate (CB7630) in patients with prostate cancer. Br J Cancer 90(12):2317\u20132325. doi:10.1038\/sj.bjc.6601879","journal-title":"Br J Cancer"},{"issue":"1","key":"239_CR42","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1586\/era.11.196","volume":"12","author":"DJ Bedoya","year":"2012","unstructured":"Bedoya DJ, Mitsiades N (2012) Abiraterone acetate, a first-in-class CYP17 inhibitor, establishes a new treatment paradigm in castration-resistant prostate cancer. Expert Rev Anticancer Ther 12(1):1\u20133. doi:10.1586\/era.11.196","journal-title":"Expert Rev Anticancer Ther"},{"key":"239_CR43","doi-asserted-by":"publisher","first-page":"9","DOI":"10.2147\/OTT.S24941","volume":"6","author":"DJ Bedoya","year":"2013","unstructured":"Bedoya DJ, Mitsiades N (2013) Clinical appraisal of abiraterone in the treatment of metastatic prostatic cancer: patient considerations, novel opportunities, and future directions. Onco Targets Ther 6:9\u201318. doi:10.2147\/OTT.S24941","journal-title":"Onco Targets Ther"},{"issue":"5928","key":"239_CR44","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1126\/science.1168175","volume":"324","author":"C Tran","year":"2009","unstructured":"Tran C, Ouk S, Clegg NJ, Chen Y, Watson PA, Arora V, Wongvipat J, Smith-Jones PM, Yoo D, Kwon A, Wasielewska T, Welsbie D, Chen CD, Higano CS, Beer TM, Hung DT, Scher HI, Jung ME, Sawyers CL (2009) Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Science 324(5928):787\u2013790. doi:10.1126\/science.1168175","journal-title":"Science"},{"issue":"28","key":"239_CR45","doi-asserted-by":"publisher","first-page":"4563","DOI":"10.1200\/JCO.2007.15.9749","volume":"26","author":"G Attard","year":"2008","unstructured":"Attard G, Reid AHM, Yap TA, Raynaud F, Dowsett M, Settatree S, Barrett M, Parker C, Martins V, Folkerd E, Clark J, Cooper CS, Kaye SB, Dearnaley D, Lee G, de Bono JS (2008) Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven. J Clin Oncol 26(28):4563\u20134571. doi:10.1200\/JCO.2007.15.9749","journal-title":"J Clin Oncol"},{"issue":"2","key":"239_CR46","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1038\/pcan.2014.8","volume":"17","author":"CJ Ryan","year":"2014","unstructured":"Ryan CJ, Peng W, Kheoh T, Welkowsky E, Haqq CM, Chandler DW, Scher HI, Molina A (2014) Androgen dynamics and serum PSA in patients treated with abiraterone acetate. Prostate Cancer Prostatic Dis 17(2):192\u2013198. doi:10.1038\/pcan.2014.8","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"9","key":"239_CR47","doi-asserted-by":"publisher","first-page":"1030","DOI":"10.1158\/2159-8290.CD-13-0142","volume":"3","author":"M Korpal","year":"2013","unstructured":"Korpal M, Korn JM, Gao X, Rakiec DP, Ruddy DA, Doshi S, Yuan J, Kovats SG, Kim S, Cooke VG, Monahan JE, Stegmeier F, Roberts TM, SELLERS WR, Zhou W, Zhu P (2013) An F876L mutation in androgen receptor confers genetic and phenotypic resistance to MDV3100 (enzalutamide). Cancer Discov 3(9):1030\u20131043. doi:10.1158\/2159-8290.CD-13-0142","journal-title":"Cancer Discov"},{"key":"239_CR48","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-14-2666","author":"AA Azad","year":"2015","unstructured":"Azad AA, Volik SV, Wyatt AW, Haegert A, Le Bihan S, Bell RH, Anderson SA, McConeghy B, Shukin R, Bazov J, Youngren J, Paris P, Thomas G, Small EJ, Wang Y, Gleave ME, Collins CC, Chi KN (2015) Androgen receptor gene aberrations in circulating cell-free DNA: biomarkers of therapeutic resistance in castration-resistant prostate cancer. Clin Cancer Res. doi:10.1158\/1078-0432.CCR-14-2666","journal-title":"Clin Cancer Res"},{"issue":"9","key":"239_CR49","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1158\/2159-8290.CD-13-0226","volume":"3","author":"JD Joseph","year":"2013","unstructured":"Joseph JD, Lu N, Qian J, Sensintaffar J, Shao G, Brigham D, Moon M, Maneval EC, Chen I, Darimont B, Hager JH (2013) A clinically relevant androgen receptor mutation confers resistance to second-generation antiandrogens enzalutamide and ARN-509. Cancer Discov 3(9):1020\u20131029. doi:10.1158\/2159-8290.CD-13-0226","journal-title":"Cancer Discov"},{"issue":"6","key":"239_CR50","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1016\/j.cell.2013.11.012","volume":"155","author":"VK Arora","year":"2013","unstructured":"Arora VK, Schenkein E, Murali R, Subudhi SK, Wongvipat J, Balbas MD, Shah N, Cai L, Efstathiou E, Logothetis C, Zheng D, Sawyers CL (2013) Glucocorticoid receptor confers resistance to antiandrogens by bypassing androgen receptor blockade. Cell 155(6):1309\u20131322. doi:10.1016\/j.cell.2013.11.012","journal-title":"Cell"},{"issue":"2","key":"239_CR51","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1007\/s12672-014-0173-2","volume":"5","author":"M Isikbay","year":"2014","unstructured":"Isikbay M, Otto K, Kregel S, Kach J, Cai Y, Vander Griend DJ, Conzen SD, Szmulewitz RZ (2014) Glucocorticoid receptor activity contributes to resistance to androgen-targeted therapy in prostate cancer. Horm Cancer 5(2):72\u201389. doi:10.1007\/s12672-014-0173-2","journal-title":"Horm Cancer"},{"issue":"18","key":"239_CR52","doi-asserted-by":"publisher","first-page":"5913","DOI":"10.1158\/1078-0432.CCR-11-0728","volume":"17","author":"EA Mostaghel","year":"2011","unstructured":"Mostaghel EA, Marck BT, Plymate SR, Vessella RL, Balk S, Matsumoto AM, Nelson PS, Montgomery RB (2011) Resistance to CYP17A1 inhibition with abiraterone in castration-resistant prostate cancer: induction of steroidogenesis and androgen receptor splice variants. Clin Cancer Res 17(18):5913\u20135925. doi:10.1158\/1078-0432.CCR-11-0728","journal-title":"Clin Cancer Res"},{"issue":"11","key":"239_CR53","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0027970","volume":"6","author":"X Zhang","year":"2011","unstructured":"Zhang X, Morrissey C, Sun S, Ketchandji M, Nelson PS, True LD, Vakar-Lopez F, Vessella RL, Plymate SR (2011) Androgen receptor variants occur frequently in castration resistant prostate cancer metastases. PLoS ONE 6(11), e27970. doi:10.1371\/journal.pone.0027970","journal-title":"PLoS ONE"},{"issue":"4","key":"239_CR54","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1007\/s12672-014-0177-y","volume":"5","author":"CCT Sprenger","year":"2014","unstructured":"Sprenger CCT, Plymate SR (2014) The link between androgen receptor splice variants and castration-resistant prostate cancer. Horm Cancer 5(4):207\u2013217. doi:10.1007\/s12672-014-0177-y","journal-title":"Horm Cancer"},{"issue":"5","key":"239_CR55","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1007\/s12672-013-0152-z","volume":"4","author":"M Mudryj","year":"2013","unstructured":"Mudryj M, Tepper CG (2013) On the origins of the androgen receptor low molecular weight species. Horm Cancer 4(5):259\u2013269. doi:10.1007\/s12672-013-0152-z","journal-title":"Horm Cancer"},{"issue":"9","key":"239_CR56","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1593\/neo.13784","volume":"15","author":"G Liu","year":"2013","unstructured":"Liu G, Sprenger C, Sun S, Epilepsia KS, Haugk K, Zhang X, Coleman I, Nelson PS, Plymate S (2013) AR variant ARv567es induces carcinogenesis in a novel transgenic mouse model of prostate cancer. Neoplasia 15(9):1009\u20131017","journal-title":"Neoplasia"},{"issue":"2","key":"239_CR57","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1158\/0008-5472.CAN-12-3630","volume":"73","author":"Y Li","year":"2013","unstructured":"Li Y, Chan SC, Brand LJ, Hwang TH, Silverstein KAT, Dehm SM (2013) Androgen receptor splice variants mediate enzalutamide resistance in castration-resistant prostate cancer cell lines. Cancer Res 73(2):483\u2013489. doi:10.1158\/0008-5472.CAN-12-3630","journal-title":"Cancer Res"},{"key":"239_CR58","doi-asserted-by":"publisher","first-page":"7654","DOI":"10.1038\/srep07654","volume":"5","author":"Y Qu","year":"2015","unstructured":"Qu Y, Dai B, Ye D, Kong Y, Chang K, Jia Z, Yang X, Zhang H, Zhu Y, Shi G (2015) Constitutively active AR-V7 plays an essential role in the development and progression of castration-resistant prostate cancer. Sci Rep 5:7654. doi:10.1038\/srep07654","journal-title":"Sci Rep"},{"issue":"11","key":"239_CR59","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.1056\/NEJMoa1315815","volume":"371","author":"ES Antonarakis","year":"2014","unstructured":"Antonarakis ES, Lu C, Wang H, Luber B, Nakazawa M, Roeser JC, Chen Y, Mohammad TA, Chen Y, Fedor HL, Lotan TL, Zheng Q, De Marzo AM, Isaacs JT, Isaacs WB, Nadal R, Paller CJ, Denmeade SR, Carducci MA, Eisenberger MA, Luo J (2014) AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer. N Engl J Med 371(11):1028\u20131038. doi:10.1056\/NEJMoa1315815","journal-title":"N Engl J Med"},{"issue":"6","key":"239_CR60","doi-asserted-by":"publisher","first-page":"1590","DOI":"10.1158\/1078-0432.CCR-13-1863","volume":"20","author":"Z Yu","year":"2014","unstructured":"Yu Z, Chen S, Sowalsky AG, Voznesensky OS, Mostaghel EA, Nelson PS, Cai C, Balk SP (2014) Rapid induction of androgen receptor splice variants by androgen deprivation in prostate cancer. Clin Cancer Res 20(6):1590\u20131600. doi:10.1158\/1078-0432.CCR-13-1863","journal-title":"Clin Cancer Res"},{"issue":"8","key":"239_CR61","doi-asserted-by":"publisher","first-page":"2348","DOI":"10.1158\/1535-7163.MCT-08-0230","volume":"7","author":"T Vasaitis","year":"2008","unstructured":"Vasaitis T, Belosay A, Schayowitz A, Khandelwal A, Chopra P, Gediya LK, Guo Z, Fang H-B, Njar VCO, Brodie AMH (2008) Androgen receptor inactivation contributes to antitumor efficacy of 17{alpha}-hydroxylase\/17,20-lyase inhibitor 3beta-hydroxy-17-(1H-benzimidazole-1-yl)androsta-5,16-diene in prostate cancer. Mol Cancer Ther 7(8):2348\u20132357. doi:10.1158\/1535-7163.MCT-08-0230","journal-title":"Mol Cancer Ther"},{"issue":"1","key":"239_CR62","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1111\/j.1749-6632.2009.03700.x","volume":"1155","author":"TM Penning","year":"2009","unstructured":"Penning TM, Byrns MC (2009) Steroid hormone transforming aldo-keto reductases and cancer. Ann N Y Acad Sci 1155(1):33\u201342. doi:10.1111\/j.1749-6632.2009.03700.x","journal-title":"Ann N Y Acad Sci"},{"key":"239_CR63","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1016\/j.jsbmb.2013.05.012","volume":"137","author":"AO Adeniji","year":"2013","unstructured":"Adeniji AO, Chen M, Penning TM (2013) AKR1C3 as a target in castrate resistant prostate cancer. J Steroid Biochem Mol Biol 137:136\u2013149. doi:10.1016\/j.jsbmb.2013.05.012","journal-title":"J Steroid Biochem Mol Biol"},{"issue":"6","key":"239_CR64","doi-asserted-by":"publisher","first-page":"2429","DOI":"10.1021\/jm3017656","volume":"56","author":"AJ Liedtke","year":"2013","unstructured":"Liedtke AJ, Adeniji AO, Chen M, Byrns MC, Jin Y, Christianson DW, Marnett LJ, Penning TM (2013) Development of potent and selective indomethacin analogues for the inhibition of AKR1C3 (Type 5 17\u03b2-hydroxysteroid dehydrogenase\/prostaglandin F synthase) in castrate-resistant prostate cancer. J Med Chem 56(6):2429\u20132446. doi:10.1021\/jm3017656","journal-title":"J Med Chem"},{"issue":"6","key":"239_CR65","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/j.ccr.2010.04.027","volume":"17","author":"RJ Andersen","year":"2010","unstructured":"Andersen RJ, Mawji NR, Wang J, Wang G, Haile S, Myung J-K, Watt K, Tam T, Yang YC, Ba\u00f1uelos CA, Williams DE, McEwan IJ, Wang Y, Sadar MD (2010) Regression of castrate-recurrent prostate cancer by a small-molecule inhibitor of the amino-terminus domain of the androgen receptor. Cancer Cell 17(6):535\u2013546. doi:10.1016\/j.ccr.2010.04.027","journal-title":"Cancer Cell"},{"issue":"2","key":"239_CR66","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.molonc.2012.02.004","volume":"6","author":"S Hoelder","year":"2012","unstructured":"Hoelder S, Clarke PA, Workman P (2012) Discovery of small molecule cancer drugs: successes, challenges and opportunities. Mol Oncol 6(2):155\u2013176. doi:10.1016\/j.molonc.2012.02.004","journal-title":"Mol Oncol"},{"issue":"1","key":"239_CR67","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1146\/annurev-pharmtox-011613-140028","volume":"54","author":"L Jin","year":"2014","unstructured":"Jin L, Wang W, Fang G (2014) Targeting protein-protein interaction by small molecules. Annu Rev Pharmacol Toxicol 54(1):435\u2013456. doi:10.1146\/annurev-pharmtox-011613-140028","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"239_CR68","doi-asserted-by":"crossref","unstructured":"Mullard A (2012) Protein-protein interaction inhibitors get into the groove. Nature reviews. Drug discovery. 173\u2013175","DOI":"10.1038\/nrd3680"},{"issue":"3","key":"239_CR69","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1021\/mp900069d","volume":"6","author":"SA Kularatne","year":"2009","unstructured":"Kularatne SA, Wang K, Santhapuram H-KR, Low PS (2009) Prostate-specific membrane antigen targeted imaging and therapy of prostate cancer using a PSMA inhibitor as a homing ligand. Mol Pharm 6(3):780\u2013789. doi:10.1021\/mp900069d","journal-title":"Mol Pharm"},{"issue":"128","key":"239_CR70","doi-asserted-by":"publisher","first-page":"128ra39","DOI":"10.1126\/scitranslmed.3003651","volume":"4","author":"J Hrkach","year":"2012","unstructured":"Hrkach J, Hoff Von D, Mukkaram Ali M, Andrianova E, Auer J, Campbell T, De Witt D, Figa M, Figueiredo M, Horhota A, Low S, McDonnell K, Peeke E, Retnarajan B, Sabnis A, Schnipper E, Song JJ, Song YH, Summa J, Tompsett D, Troiano G, Van Geen Hoven T, Wright J, LoRusso P, Kantoff PW, Bander NH, Sweeney C, Farokhzad OC, Langer R, Zale S (2012) Preclinical development and clinical translation of a PSMA-targeted docetaxel nanoparticle with a differentiated pharmacological profile. Sci Transl Med 4(128):128ra39\u2013128ra39. doi:10.1126\/scitranslmed.3003651","journal-title":"Sci Transl Med"},{"issue":"7","key":"239_CR71","doi-asserted-by":"publisher","first-page":"2948","DOI":"10.1172\/JCI66398","volume":"123","author":"J-K Myung","year":"2013","unstructured":"Myung J-K, Ba\u00f1uelos CA, Fernandez JG, Mawji NR, Wang J, Tien AH, Yang YC, Tavakoli I, Haile S, Watt K, McEwan IJ, Plymate S, Andersen RJ, Sadar MD (2013) An androgen receptor N-terminal domain antagonist for treating prostate cancer. J Clin Invest 123(7):2948\u20132960. doi:10.1172\/JCI66398","journal-title":"J Clin Invest"},{"issue":"45","key":"239_CR72","doi-asserted-by":"publisher","first-page":"28697","DOI":"10.1074\/jbc.271.45.28697","volume":"271","author":"Y Fang","year":"1996","unstructured":"Fang Y, Fliss AE, Robins DM, Caplan AJ (1996) Hsp90 regulates androgen receptor hormone binding affinity in vivo. J Biol Chem 271(45):28697\u201328702","journal-title":"J Biol Chem"},{"issue":"5962","key":"239_CR73","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1038\/308850a0","volume":"308","author":"I Joab","year":"1984","unstructured":"Joab I, Radanyi C, Renoir M, Buchou T, Catelli MG, Binart N, Mester J, Baulieu EE (1984) Common non-hormone binding component in non-transformed chick oviduct receptors of four steroid hormones. Nature 308(5962):850\u2013853","journal-title":"Nature"},{"issue":"32","key":"239_CR74","doi-asserted-by":"publisher","first-page":"7422","DOI":"10.1021\/bi00147a029","volume":"31","author":"J Veldscholte","year":"1992","unstructured":"Veldscholte J, Berrevoets CA, Zegers ND, van der Kwast TH, Grootegoed JA, Mulder E (1992) Hormone-induced dissociation of the androgen receptor-heat-shock protein complex: use of a new monoclonal antibody to distinguish transformed from nontransformed receptors. Biochemistry 31(32):7422\u20137430","journal-title":"Biochemistry"},{"issue":"3","key":"239_CR75","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1210\/edrv.18.3.0303","volume":"18","author":"WB Pratt","year":"1997","unstructured":"Pratt WB, Toft DO (1997) Steroid receptor interactions with heat shock protein and immunophilin chaperones. Endocr Rev 18(3):306\u2013360. doi:10.1210\/edrv.18.3.0303","journal-title":"Endocr Rev"},{"issue":"1","key":"239_CR76","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1379\/1466-1268(2002)007<0055:EOGOAR>2.0.CO;2","volume":"7","author":"DK Vanaja","year":"2002","unstructured":"Vanaja DK, Mitchell SH, Toft DO, Young CYF (2002) Effect of geldanamycin on androgen receptor function and stability. Cell Stress Chaperones 7(1):55\u201364","journal-title":"Cell Stress Chaperones"},{"issue":"4","key":"239_CR77","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1007\/BF00689048","volume":"36","author":"JG Supko","year":"1995","unstructured":"Supko JG, Hickman RL, Grever MR, Malspeis L (1995) Preclinical pharmacologic evaluation of geldanamycin as an antitumor agent. Cancer Chemother Pharmacol 36(4):305\u2013315. doi:10.1007\/BF00689048","journal-title":"Cancer Chemother Pharmacol"},{"issue":"23","key":"239_CR78","doi-asserted-by":"publisher","first-page":"7940","DOI":"10.1158\/1078-0432.CCR-08-0221","volume":"14","author":"EI Heath","year":"2008","unstructured":"Heath EI, Hillman DW, Vaishampayan U, Sheng S, Sarkar F, Harper F, Gaskins M, Pitot HC, Tan W, Ivy SP, Pili R, Carducci MA, Erlichman C, Liu G (2008) A phase II trial of 17-allylamino-17-demethoxygeldanamycin in patients with hormone-refractory metastatic prostate cancer. Clin Cancer Res 14(23):7940\u20137946. doi:10.1158\/1078-0432.CCR-08-0221","journal-title":"Clin Cancer Res"},{"issue":"1","key":"239_CR79","doi-asserted-by":"publisher","first-page":"35","DOI":"10.3892\/ijo.2012.1698","volume":"42","author":"S He","year":"2013","unstructured":"He S, Zhang C, Shafi AA, Sequeira M, Acquaviva J, Friedland JC, Sang J, Smith DL, Weigel NL, Wada Y, Proia DA (2013) Potent activity of the Hsp90 inhibitor ganetespib in prostate cancer cells irrespective of androgen receptor status or variant receptor expression. Int J Oncol 42(1):35\u201343. doi:10.3892\/ijo.2012.1698","journal-title":"Int J Oncol"},{"key":"239_CR80","doi-asserted-by":"crossref","unstructured":"Heath EI, Stein MN, Vaishampayan U, Antonarakis ES, Liu G, Sheng S, Farrow K, Smith DW, Heilbrun LK (2013) Phase II trial of single-agent ganetespib (STA-9090), a heat shock protein 90 (Hsp90) inhibitor in heavily pretreated patients with metastatic castration-resistant prostate cancer (mCRPC) post docetaxel-based chemotherapy: results of a Prostate Cancer Clinical Trials Consortium (PCCTC) study. J Clin Oncol 31:(suppl\u2013abstr 5085)","DOI":"10.1200\/jco.2013.31.15_suppl.5085"},{"issue":"6","key":"239_CR81","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1016\/j.steroids.2012.12.013","volume":"78","author":"AA Shafi","year":"2013","unstructured":"Shafi AA, Cox MB, Weigel NL (2013) Androgen receptor splice variants are resistant to inhibitors of Hsp90 and FKBP52, which alter androgen receptor activity and expression. Steroids 78(6):548\u2013554. doi:10.1016\/j.steroids.2012.12.013","journal-title":"Steroids"},{"issue":"9","key":"239_CR82","doi-asserted-by":"publisher","first-page":"2876","DOI":"10.1073\/pnas.0400116101","volume":"101","author":"C Elbi","year":"2004","unstructured":"Elbi C, Walker DA, Romero G, Sullivan WP, Toft DO, Hager GL, DeFranco DB (2004) Molecular chaperones function as steroid receptor nuclear mobility factors. Proc Natl Acad Sci 101(9):2876\u20132881. doi:10.1073\/pnas.0400116101","journal-title":"Proc Natl Acad Sci"},{"issue":"5576","key":"239_CR83","doi-asserted-by":"publisher","first-page":"2232","DOI":"10.1126\/science.1073051","volume":"296","author":"BC Freeman","year":"2002","unstructured":"Freeman BC, Yamamoto KR (2002) Disassembly of transcriptional regulatory complexes by molecular chaperones. Science 296(5576):2232\u20132235. doi:10.1126\/science.1073051","journal-title":"Science"},{"issue":"10","key":"239_CR84","doi-asserted-by":"publisher","first-page":"1694","DOI":"10.1210\/me.2012-1056","volume":"26","author":"V Reebye","year":"2012","unstructured":"Reebye V, Querol Cano L, Lavery DN, Brooke GN, Powell SM, Chotai D, Walker MM, Whitaker HC, Wait R, Hurst HC, Bevan CL (2012) Role of the HSP90-associated cochaperone p23 in enhancing activity of the androgen receptor and significance for prostate cancer. Mol Endocrinol 26(10):1694\u20131706. doi:10.1210\/me.2012-1056","journal-title":"Mol Endocrinol"},{"issue":"42","key":"239_CR85","doi-asserted-by":"publisher","first-page":"39858","DOI":"10.1074\/jbc.M206322200","volume":"277","author":"AD Basso","year":"2002","unstructured":"Basso AD, Solit DB, Chiosis G, Giri B, Tsichlis P, Rosen N (2002) Akt forms an intracellular complex with heat shock protein 90 (Hsp90) and Cdc37 and is destabilized by inhibitors of Hsp90 function. J Biol Chem 277(42):39858\u201339866. doi:10.1074\/jbc.M206322200","journal-title":"J Biol Chem"},{"issue":"2","key":"239_CR86","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1016\/S1097-2765(02)00459-8","volume":"9","author":"LA Cirillo","year":"2002","unstructured":"Cirillo LA, Lin FR, Cuesta I, Friedman D, Jarnik M, Zaret KS (2002) Opening of compacted chromatin by early developmental transcription factors HNF3 (FoxA) and GATA-4. Mol Cell 9(2):279\u2013289","journal-title":"Mol Cell"},{"issue":"6436","key":"239_CR87","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1038\/364412a0","volume":"364","author":"KL Clark","year":"1993","unstructured":"Clark KL, Halay ED, Lai E, Burley SK (1993) Co-crystal structure of the HNF-3\/fork head DNA-recognition motif resembles histone H5. Nature 364(6436):412\u2013420. doi:10.1038\/364412a0","journal-title":"Nature"},{"issue":"8","key":"239_CR88","doi-asserted-by":"publisher","first-page":"1484","DOI":"10.1210\/me.2003-0020","volume":"17","author":"N Gao","year":"2003","unstructured":"Gao N, Zhang J, Rao MA, Case TC, Mirosevich J, Wang Y, Jin R, Gupta A, Rennie PS, Matusik RJ (2003) The role of hepatocyte nuclear factor-3 alpha (Forkhead Box A1) and androgen receptor in transcriptional regulation of prostatic genes. Mol Endocrinol 17(8):1484\u20131507. doi:10.1210\/me.2003-0020","journal-title":"Mol Endocrinol"},{"issue":"3","key":"239_CR89","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1016\/j.molcel.2007.05.041","volume":"27","author":"Q Wang","year":"2007","unstructured":"Wang Q, Li W, Liu XS, Carroll JS, JAnne OA, Keeton EK, Chinnaiyan AM, Pienta KJ, Brown M (2007) A hierarchical network of transcription factors governs androgen receptor-dependent prostate cancer growth. Mol Cell 27(3):380\u2013392. doi:10.1016\/j.molcel.2007.05.041","journal-title":"Mol Cell"},{"issue":"2","key":"239_CR90","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/j.cell.2009.04.056","volume":"138","author":"Q Wang","year":"2009","unstructured":"Wang Q, Li W, Zhang Y, Yuan X, Xu K, Yu J, Chen Z, Beroukhim R, Wang H, Lupien M, Wu T, Regan MM, Meyer CA, Carroll JS, Manrai AK, JAnne OA, Balk SP, Mehra R, Han B, Chinnaiyan AM, Rubin MA, True L, Fiorentino M, Fiore C, Loda M, Kantoff PW, Liu XS, Brown M (2009) Androgen receptor regulates a distinct transcription program in androgen-independent prostate cancer. Cell 138(2):245\u2013256. doi:10.1016\/j.cell.2009.04.056","journal-title":"Cell"},{"issue":"2","key":"239_CR91","doi-asserted-by":"publisher","first-page":"848","DOI":"10.1016\/j.ajpath.2011.10.021","volume":"180","author":"J Gerhardt","year":"2012","unstructured":"Gerhardt J, Montani M, Wild P, Beer M, Huber F, Hermanns T, M\u00fcntener M, Kristiansen G (2012) FOXA1 promotes tumor progression in prostate cancer and represents a novel hallmark of castration-resistant prostate cancer. Am J Pathol 180(2):848\u2013861. doi:10.1016\/j.ajpath.2011.10.021","journal-title":"Am J Pathol"},{"issue":"19","key":"239_CR92","doi-asserted-by":"publisher","first-page":"3962","DOI":"10.1038\/emboj.2011.328","volume":"30","author":"B Sahu","year":"2011","unstructured":"Sahu B, Laakso M, Ovaska K, Mirtti T, Lundin J, Rannikko A, Sankila A, Turunen J-P, Lundin M, Konsti J, Vesterinen T, Nordling S, Kallioniemi O, Hautaniemi S, JAnne OA (2011) Dual role of FoxA1 in androgen receptor binding to chromatin, androgen signalling and prostate cancer. EMBO J 30(19):3962\u20133976. doi:10.1038\/emboj.2011.328","journal-title":"EMBO J"},{"issue":"50","key":"239_CR93","doi-asserted-by":"publisher","first-page":"5666","DOI":"10.1038\/onc.2013.508","volume":"33","author":"JLL Robinson","year":"2014","unstructured":"Robinson JLL, Hickey TE, Warren AY, Vowler SL, Carroll T, Lamb AD, Papoutsoglou N, Neal DE, Tilley WD, Carroll JS (2014) Elevated levels of FOXA1 facilitate androgen receptor chromatin binding resulting in a CRPC-like phenotype. Oncogene 33(50):5666\u20135674. doi:10.1038\/onc.2013.508","journal-title":"Oncogene"},{"key":"239_CR94","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/ncomms4972","volume":"5","author":"H-J Jin","year":"2014","unstructured":"Jin H-J, Zhao JC, Wu L, Kim J, Yu J (2014) Cooperativity and equilibrium with FOXA1 define the androgen receptor transcriptional program. Nat Commun 5:1\u201314. doi:10.1038\/ncomms4972","journal-title":"Nat Commun"},{"issue":"7351","key":"239_CR95","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1038\/nature10006","volume":"474","author":"D Wang","year":"2011","unstructured":"Wang D, Garcia-Bassets I, Benner C, Li W, Su X, Zhou Y, Qiu J, Liu W, Kaikkonen MU, Ohgi KA, Glass CK, Rosenfeld MG, Fu X-D (2011) Reprogramming transcription by distinct classes of enhancers functionally defined by eRNA. Nature 474(7351):390\u2013394. doi:10.1038\/nature10006","journal-title":"Nature"},{"key":"239_CR96","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.biocel.2014.06.013","volume":"54","author":"WC Krause","year":"2014","unstructured":"Krause WC, Shafi AA, Nakka M, Weigel NL (2014) Androgen receptor and its splice variant, AR-V7, differentially regulate FOXA1 sensitive genes in LNCaP prostate cancer cells. Int J Biochem Cell Biol 54:49\u201359. doi:10.1016\/j.biocel.2014.06.013","journal-title":"Int J Biochem Cell Biol"},{"issue":"43","key":"239_CR97","doi-asserted-by":"publisher","first-page":"3847","DOI":"10.1038\/onc.2009.243","volume":"28","author":"M B\u00f6hm","year":"2009","unstructured":"B\u00f6hm M, Locke WJ, Sutherland RL, Kench JG, Henshall SM (2009) A role for GATA-2 in transition to an aggressive phenotype in prostate cancer through modulation of key androgen-regulated genes. Oncogene 28(43):3847\u20133856. doi:10.1038\/onc.2009.243","journal-title":"Oncogene"},{"key":"239_CR98","doi-asserted-by":"publisher","unstructured":"He B, Lanz RB, Fiskus W, Geng C, Yi P, Hartig SM, Rajapakshe K, Shou J, Wei L, Shah SS, Foley C, Chew SA, Eedunuri VK, Bedoya DJ, Feng Q, Minami T, Mitsiades CS, Frolov A, Weigel NL, Hilsenbeck SG, Rosen DG, Palzkill T, Ittmann MM, Song Y, Coarfa C, O\u2019Malley BW, Mitsiades N (2014) GATA2 facilitates steroid receptor coactivator recruitment to the androgen receptor complex. Proc Natl Acad Sci U.S.A. 201421415. doi:10.1073\/pnas.1421415111","DOI":"10.1073\/pnas.1421415111"},{"issue":"2","key":"239_CR99","doi-asserted-by":"publisher","first-page":"451","DOI":"10.18632\/oncotarget.1296","volume":"5","author":"YT Chiang","year":"2014","unstructured":"Chiang YT, Wang K, Fazli L, Qi RZ, Gleave ME, Collins CC, Gout PW, Wang Y (2014) GATA2 as a potential metastasis-driving gene in prostate cancer. Oncotarget 5(2):451\u2013461","journal-title":"Oncotarget"},{"issue":"6","key":"239_CR100","doi-asserted-by":"publisher","first-page":"3607","DOI":"10.1093\/nar\/gkt1382","volume":"42","author":"D Wu","year":"2014","unstructured":"Wu D, Sunkel B, Chen Z, Liu X, Ye Z, Li Q, Grenade C, Ke J, Zhang C, Chen H, Nephew KP, Huang TH-M, Liu Z, Jin VX, Wang Q (2014) Three-tiered role of the pioneer factor GATA2 in promoting androgen-dependent gene expression in prostate cancer. Nucleic Acids Res 42(6):3607\u20133622. doi:10.1093\/nar\/gkt1382","journal-title":"Nucleic Acids Res"},{"key":"239_CR101","doi-asserted-by":"publisher","unstructured":"Chi P, Rockowitz S, Iaquinta PJ, Shamu T, Shukla S, Gao D, Sirota I, Carver BS, Wongvipat J, Scher HI, Zheng D, Chen Y, Sawyers CL (2013) ETS factors reprogram the androgen receptor cistrome and prime prostate tumorigenesis in response to PTEN loss. Nat Med 1\u20139. doi:10.1038\/nm.3216","DOI":"10.1038\/nm.3216"},{"issue":"2","key":"239_CR102","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/j.ccell.2014.11.013","volume":"27","author":"SJ Vidal","year":"2015","unstructured":"Vidal SJ, Rodriguez-Bravo V, Quinn SA, Rodriguez-Barrueco R, Lujambio A, Williams E, Sun X, de la Iglesia-Vicente J, Lee A, Readhead B, Chen X, Galsky M, Esteve B, Petrylak DP, Dudley JT, Rabadan R, Silva JM, Hoshida Y, Lowe SW, Cordon-Cardo C, Domingo-Domenech J (2015) A targetable GATA2-IGF2 axis confers aggressiveness in lethal prostate cancer. Cancer Cell 27(2):223\u2013239. doi:10.1016\/j.ccell.2014.11.013","journal-title":"Cancer Cell"},{"issue":"5","key":"239_CR103","first-page":"1833","volume":"6","author":"MM Tanner","year":"2000","unstructured":"Tanner MM, Grenman S, Koul A, Johannsson O, Meltzer P, Pejovic T, Borg A, Isola JJ (2000) Frequent amplification of chromosomal region 20q12-q13 in ovarian cancer. Clin Cancer Res 6(5):1833\u20131839","journal-title":"Clin Cancer Res"},{"issue":"11","key":"239_CR104","doi-asserted-by":"publisher","first-page":"2346","DOI":"10.1002\/cncr.10963","volume":"95","author":"Y Wang","year":"2002","unstructured":"Wang Y, Wu M-C, Sham JST, Zhang W, Wu W-Q, Guan X-Y (2002) Prognostic significance ofc-myc andAIB1 amplification in hepatocellular carcinoma. Cancer 95(11):2346\u20132352. doi:10.1002\/cncr.10963","journal-title":"Cancer"},{"issue":"1","key":"239_CR105","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1016\/j.ygyno.2003.10.007","volume":"92","author":"SM Kershah","year":"2004","unstructured":"Kershah SM, Desouki MM, Koterba KL, Rowan BG (2004) Expression of estrogen receptor coregulators in normal and malignant human endometrium. Gynecol Oncol 92(1):304\u2013313. doi:10.1016\/j.ygyno.2003.10.007","journal-title":"Gynecol Oncol"},{"issue":"19","key":"239_CR106","doi-asserted-by":"publisher","first-page":"5631","DOI":"10.1158\/0008-5472.CAN-14-0476","volume":"74","author":"C Geng","year":"2014","unstructured":"Geng C, Rajapakshe K, Shah SS, Shou J, Eedunuri VK, Foley C, Fiskus W, Rajendran M, Chew SA, Zimmermann M, Bond R, He B, Coarfa C, Mitsiades N (2014) Androgen receptor is the key transcriptional mediator of the tumor suppressor SPOP in prostate cancer. Cancer Res 74(19):5631\u20135643. doi:10.1158\/0008-5472.CAN-14-0476","journal-title":"Cancer Res"},{"issue":"17","key":"239_CR107","doi-asserted-by":"publisher","first-page":"7976","DOI":"10.1158\/0008-5472.CAN-04-4076","volume":"65","author":"H-J Zhou","year":"2005","unstructured":"Zhou H-J, YAN J, Luo W, Ayala G, Lin S-H, Erdem H, Ittmann M, Tsai SY, Tsai M-J (2005) SRC-3 is required for prostate cancer cell proliferation and survival. Cancer Res 65(17):7976\u20137983. doi:10.1158\/0008-5472.CAN-04-4076","journal-title":"Cancer Res"},{"issue":"11","key":"239_CR108","doi-asserted-by":"publisher","first-page":"5013","DOI":"10.1172\/JCI76412","volume":"124","author":"J Qin","year":"2014","unstructured":"Qin J, Lee H-J, Wu S-P, Lin S-C, Lanz RB, Creighton CJ, DeMayo FJ, Tsai SY, Tsai M-J (2014) Androgen deprivation-induced NCoA2 promotes metastatic and castration-resistant prostate cancer. J Clin Invest 124(11):5013\u20135026. doi:10.1172\/JCI76412","journal-title":"J Clin Invest"},{"key":"239_CR109","doi-asserted-by":"publisher","unstructured":"Xu J, Wu R-C, O\u2019Malley BW (2009) Normal and cancer-related functions of the p160 steroid receptor co-activator (SRC) family. 1\u201316. doi:10.1038\/nrc2695","DOI":"10.1038\/nrc2695"},{"issue":"7","key":"239_CR110","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1016\/j.tem.2014.05.004","volume":"25","author":"E Stashi","year":"2014","unstructured":"Stashi E, York B, O\u2019Malley BW (2014) Steroid receptor coactivators: servants and masters for control of systems metabolism. Trends Endocrinol Metab 25(7):337\u2013347. doi:10.1016\/j.tem.2014.05.004","journal-title":"Trends Endocrinol Metab"},{"key":"239_CR111","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1146\/annurev-med-051812-145316","volume":"65","author":"S Dasgupta","year":"2014","unstructured":"Dasgupta S, Lonard DM, O\u2019Malley BW (2014) Nuclear receptor coactivators: master regulators of human health and disease. Annu Rev Med 65:279\u2013292. doi:10.1146\/annurev-med-051812-145316","journal-title":"Annu Rev Med"},{"issue":"1","key":"239_CR112","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/S0378-1119(00)00024-X","volume":"245","author":"C Leo","year":"2000","unstructured":"Leo C, Chen JD (2000) The SRC family of nuclear receptor coactivators. Gene 245(1):1\u201311","journal-title":"Gene"},{"issue":"4","key":"239_CR113","doi-asserted-by":"publisher","first-page":"2396","DOI":"10.1074\/jbc.M106312200","volume":"277","author":"T Kino","year":"2002","unstructured":"Kino T, Slobodskaya O, Pavlakis GN, Chrousos GP (2002) Nuclear receptor coactivator p160 proteins enhance the HIV-1 long terminal repeat promoter by bridging promoter-bound factors and the Tat-P-TEFb complex. J Biol Chem 277(4):2396\u20132405. doi:10.1074\/jbc.M106312200","journal-title":"J Biol Chem"},{"issue":"4","key":"239_CR114","doi-asserted-by":"publisher","DOI":"10.2196\/jmir.1827","volume":"13","author":"Z Gao","year":"2005","unstructured":"Gao Z, Chiao P, Zhang X, Lazar M, Seto E, Young HA, Ye J (2005) Coactivators and corepressors of NF-KB in IkB alpha gene promoter. J Biol Chem 13(4), e97. doi:10.2196\/jmir.1827","journal-title":"J Biol Chem"},{"issue":"4","key":"239_CR115","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1016\/j.biocel.2012.12.012","volume":"45","author":"M Nakka","year":"2013","unstructured":"Nakka M, Agoulnik IU, Weigel NL (2013) Targeted disruption of the p160 coactivator interface of androgen receptor (AR) selectively inhibits AR activity in both androgen-dependent and castration-resistant AR-expressing prostate cancer cells. Int J Biochem Cell Biol 45(4):763\u2013772. doi:10.1016\/j.biocel.2012.12.012","journal-title":"Int J Biochem Cell Biol"},{"issue":"27","key":"239_CR116","doi-asserted-by":"publisher","first-page":"16651","DOI":"10.1074\/jbc.273.27.16651","volume":"273","author":"SK Lee","year":"1998","unstructured":"Lee SK, Kim HJ, Na SY, Kim TS, Choi HS, Im SY, Lee JW (1998) Steroid receptor coactivator-1 coactivates activating protein-1-mediated transactivations through interaction with the c-Jun and c-Fos subunits. J Biol Chem 273(27):16651\u201316654","journal-title":"J Biol Chem"},{"issue":"29","key":"239_CR117","doi-asserted-by":"publisher","first-page":"26031","DOI":"10.1074\/jbc.M110865200","volume":"277","author":"SS Koh","year":"2002","unstructured":"Koh SS, Li H, Lee Y-H, Widelitz RB, Chuong C-M, Stallcup MR (2002) Synergistic coactivator function by coactivator-associated arginine methyltransferase (CARM) 1 and beta-catenin with two different classes of DNA-binding transcriptional activators. J Biol Chem 277(29):26031\u201326035. doi:10.1074\/jbc.M110865200","journal-title":"J Biol Chem"},{"issue":"30","key":"239_CR118","doi-asserted-by":"publisher","first-page":"22986","DOI":"10.1074\/jbc.M002807200","volume":"275","author":"B He","year":"2000","unstructured":"He B, Kemppainen JA, Wilson EM (2000) FXXLF and WXXLF sequences mediate the NH2-terminal interaction with the ligand binding domain of the androgen receptor. J Biol Chem 275(30):22986\u201322994. doi:10.1074\/jbc.M002807200","journal-title":"J Biol Chem"},{"issue":"21","key":"239_CR119","doi-asserted-by":"publisher","first-page":"3343","DOI":"10.1101\/gad.12.21.3343","volume":"12","author":"BD Darimont","year":"1998","unstructured":"Darimont BD, Wagner RL, Apriletti JW, Stallcup MR, Kushner PJ, Baxter JD, Fletterick RJ, Yamamoto KR (1998) Structure and specificity of nuclear receptor-coactivator interactions. Genes Dev 12(21):3343\u20133356. doi:10.1101\/gad.12.21.3343","journal-title":"Genes Dev"},{"issue":"3","key":"239_CR120","doi-asserted-by":"publisher","first-page":"1032","DOI":"10.1158\/1078-0432.CCR-0990-3","volume":"10","author":"MJ Linja","year":"2004","unstructured":"Linja MJ, Porkka KP, Kang Z, Savinainen KJ, JAnne OA, Tammela TLJ, Vessella RL, Palvimo JJ, Visakorpi T (2004) Expression of androgen receptor coregulators in prostate cancer. Clin Cancer Res 10(3):1032\u20131040","journal-title":"Clin Cancer Res"},{"issue":"1","key":"239_CR121","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.ccr.2010.05.026","volume":"18","author":"BS Taylor","year":"2010","unstructured":"Taylor BS, Schultz N, Hieronymus H, Gopalan A, Xiao Y, Carver BS, Arora VK, Kaushik P, Cerami E, Reva B, Antipin Y, Mitsiades N, Landers T, Dolgalev I, Major JE, Wilson M, Socci ND, Lash AE, Heguy A, Eastham JA, Scher HI, Reuter VE, Scardino PT, Sander C, Sawyers CL, Gerald WL (2010) Integrative genomic profiling of human prostate cancer. Cancer Cell 18(1):11\u201322. doi:10.1016\/j.ccr.2010.05.026","journal-title":"Cancer Cell"},{"issue":"8","key":"239_CR122","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1016\/j.steroids.2009.02.007","volume":"74","author":"IU Agoulnik","year":"2009","unstructured":"Agoulnik IU, Weigel NL (2009) Coactivator selective regulation of androgen receptor activity. Steroids 74(8):669\u2013674. doi:10.1016\/j.steroids.2009.02.007","journal-title":"Steroids"},{"issue":"17","key":"239_CR123","doi-asserted-by":"publisher","first-page":"7959","DOI":"10.1158\/0008-5472.CAN-04-3541","volume":"65","author":"IU Agoulnik","year":"2005","unstructured":"Agoulnik IU, Vaid A, Bingman WE, Erdeme H, Frolov A, Smith CL, Ayala G, Ittmann MM, Weigel NL (2005) Role of SRC-1 in the promotion of prostate cancer cell growth and tumor progression. Cancer Res 65(17):7959\u20137967. doi:10.1158\/0008-5472.CAN-04-3541","journal-title":"Cancer Res"},{"issue":"21","key":"239_CR124","doi-asserted-by":"publisher","first-page":"10594","DOI":"10.1158\/0008-5472.CAN-06-1023","volume":"66","author":"IU Agoulnik","year":"2006","unstructured":"Agoulnik IU, Vaid A, Nakka M, Alvarado M, Bingman WE, Erdem H, Frolov A, Smith CL, Ayala GE, Ittmann MM, Weigel NL (2006) Androgens modulate expression of transcription intermediary factor 2, an androgen receptor coactivator whose expression level correlates with early biochemical recurrence in prostate cancer. Cancer Res 66(21):10594\u201310602. doi:10.1158\/0008-5472.CAN-06-1023","journal-title":"Cancer Res"},{"issue":"12","key":"239_CR125","doi-asserted-by":"publisher","first-page":"1928","DOI":"10.1054\/bjoc.2001.2179","volume":"85","author":"VJ Gnanapragasam","year":"2001","unstructured":"Gnanapragasam VJ, Leung HY, Pulimood AS, Neal DE, Robson CN (2001) Expression of RAC 3, a steroid hormone receptor co-activator in prostate cancer. Br J Cancer 85(12):1928\u20131936. doi:10.1054\/bjoc.2001.2179","journal-title":"Br J Cancer"},{"key":"239_CR126","doi-asserted-by":"publisher","unstructured":"Geng C, He B, Xu L, Barbieri CE (2013) Prostate cancer-associated mutations in speckle-type POZ protein (SPOP) regulate steroid receptor coactivator 3 protein turnover. In. doi:10.1073\/pnas.1304502110\/-\/DCSupplemental","DOI":"10.1073\/pnas.1304502110\/-\/DCSupplemental"},{"issue":"6205","key":"239_CR127","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1126\/science.1250255","volume":"346","author":"J-PP Theurillat","year":"2014","unstructured":"Theurillat J-PP, Udeshi ND, Errington WJ, Svinkina T, Baca SC, Pop M, Wild PJ, Blattner M, Groner AC, Rubin MA, Moch H, Priv\u00e9 GG, Carr SA, Garraway LA (2014) Prostate cancer. Ubiquitylome analysis identifies dysregulation of effector substrates in SPOP-mutant prostate cancer. Science 346(6205):85\u201389. doi:10.1126\/science.1250255","journal-title":"Science"},{"issue":"22","key":"239_CR128","doi-asserted-by":"publisher","first-page":"11039","DOI":"10.1158\/0008-5472.CAN-06-2442","volume":"66","author":"J Yan","year":"2006","unstructured":"Yan J, YU C-T, Ozen M, Ittmann M, Tsai SY, Tsai M-J (2006) Steroid receptor coactivator-3 and activator protein-1 coordinately regulate the transcription of components of the insulin-like growth factor\/AKT signaling pathway. Cancer Research 66(22):11039\u201311046. doi:10.1158\/0008-5472.CAN-06-2442","journal-title":"Cancer Research"},{"issue":"13","key":"239_CR129","doi-asserted-by":"publisher","first-page":"5460","DOI":"10.1158\/0008-5472.CAN-08-0955","volume":"68","author":"J YAN","year":"2008","unstructured":"YAN J, Erdem H, Li R, Cai Y, Ayala G, Ittmann M, Yu-Lee L-Y, Tsai SY, Tsai M-J (2008) Steroid receptor coactivator-3\/AIB1 promotes cell migration and invasiveness through focal adhesion turnover and matrix metalloproteinase expression. Cancer Res 68(13):5460\u20135468. doi:10.1158\/0008-5472.CAN-08-0955","journal-title":"Cancer Res"},{"issue":"3","key":"239_CR130","doi-asserted-by":"publisher","first-page":"256","DOI":"10.7150\/ijbs.5.256","volume":"5","author":"JC-Y Tien","year":"2009","unstructured":"Tien JC-Y, Zhou S, Xu J (2009) The role of SRC-1 in murine prostate cancinogenesis is nonessential due to a possible compensation of SRC-3\/AIB1 overexpression. Int J Biol Sci 5(3):256\u2013264","journal-title":"Int J Biol Sci"},{"issue":"1","key":"239_CR131","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1677\/erc.0.0110117","volume":"11","author":"SM Powell","year":"2004","unstructured":"Powell SM, Christiaens V, Voulgaraki D, Waxman J, Claessens F, Bevan CL (2004) Mechanisms of androgen receptor signalling via steroid receptor coactivator-1 in prostate. Endocr Relat Cancer 11(1):117\u2013130","journal-title":"Endocr Relat Cancer"},{"issue":"10","key":"239_CR132","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1002\/pros.22649","volume":"73","author":"LR Bohrer","year":"2013","unstructured":"Bohrer LR, Liu P, Zhong J, Pan Y, Angstman J, Brand LJ, Dehm SM, Huang H (2013) FOXO1 binds to the TAU5 motif and inhibits constitutively active androgen receptor splice variants. Prostate 73(10):1017\u20131027. doi:10.1002\/pros.22649","journal-title":"Prostate"},{"issue":"12","key":"239_CR133","doi-asserted-by":"publisher","first-page":"2041","DOI":"10.1210\/me.2011-1222","volume":"25","author":"Y Wang","year":"2011","unstructured":"Wang Y, Lonard DM, Yu Y, Chow D-C, Palzkill TG, O\u2019Malley BW (2011) Small molecule inhibition of the steroid receptor coactivators, SRC-3 and SRC-1. Mol Endocrinol 25(12):2041\u20132053. doi:10.1210\/me.2011-1222","journal-title":"Mol Endocrinol"},{"issue":"5","key":"239_CR134","doi-asserted-by":"publisher","first-page":"1506","DOI":"10.1158\/0008-5472.CAN-13-2939","volume":"74","author":"Y Wang","year":"2014","unstructured":"Wang Y, Lonard DM, Yu Y, Chow D-C, Palzkill TG, Wang J, Qi R, Matzuk AJ, Song X, Madoux F, Hodder P, Chase P, Griffin PR, Zhou S, Liao L, Xu J, O\u2019Malley BW (2014) Bufalin is a potent small-molecule inhibitor of the steroid receptor coactivators SRC-3 and SRC-1. Cancer Res 74(5):1506\u20131517. doi:10.1158\/0008-5472.CAN-13-2939","journal-title":"Cancer Res"},{"issue":"4","key":"239_CR135","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0095243","volume":"9","author":"F Yan","year":"2014","unstructured":"Yan F, Yu Y, Chow D-C, Palzkill T, Madoux F, Hodder P, Chase P, Griffin PR, O\u2019Malley BW, Lonard DM (2014) Identification of verrucarin A as a potent and selective steroid receptor coactivator-3 small molecule inhibitor. Agoulnik IU, ed. PLoS ONE 9(4), e95243. doi:10.1371\/journal.pone.0095243","journal-title":"PLoS ONE"},{"key":"239_CR136","doi-asserted-by":"publisher","unstructured":"Kumar Eedunuri V, Rajapakshe K, Fiskus W, Geng C, Anne Chew S, Foley C, Shah SS, Shou J, Mohamed JS, Coarfa C, O\u2019Malley BW, Mitsiades N (2015) MiR137 targets p160 Steroid Receptor Coactivators SRC1, SRC2 and SRC3 and inhibits cell proliferation. Mol Endocrinol. me20151080. doi:10.1210\/me.2015-1080","DOI":"10.1210\/me.2015-1080"},{"issue":"6595","key":"239_CR137","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1038\/383099a0","volume":"383","author":"D Chakravarti","year":"1996","unstructured":"Chakravarti D, LaMorte VJ, Nelson MC, Nakajima T (1996) Role of CBP\/P300 in nuclear receptor signalling. Nature 383(6595):99\u2013103. doi:10.1038\/383099a0","journal-title":"Nature"},{"issue":"20","key":"239_CR138","first-page":"5632","volume":"62","author":"JD Debes","year":"2002","unstructured":"Debes JD, Schmidt LJ, Huang H, Tindall DJ (2002) p300 mediates androgen-independent transactivation of the androgen receptor by interleukin 6. Cancer Res 62(20):5632\u20135636","journal-title":"Cancer Res"},{"issue":"1","key":"239_CR139","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1016\/S0002-9440(10)63814-X","volume":"162","author":"B Comuzzi","year":"2003","unstructured":"Comuzzi B, Lambrinidis L, Rogatsch H, Godoy-Tundidor S, Knezevic N, Krhen I, Marekovic Z, Bartsch G, Klocker H, Hobisch A, Culig Z (2003) The transcriptional co-activator cAMP response element-binding protein-binding protein is expressed in prostate cancer and enhances androgen- and anti-androgen-induced androgen receptor function. Am J Pathol 162(1):233\u2013241. doi:10.1016\/S0002-9440(10)63814-X","journal-title":"Am J Pathol"},{"issue":"9","key":"239_CR140","doi-asserted-by":"publisher","first-page":"1644","DOI":"10.1158\/1535-7163.MCT-11-0182","volume":"10","author":"FR Santer","year":"2011","unstructured":"Santer FR, H\u00f6schele PPS, Oh SJ, Erb HHH, Bouchal J, Cavarretta IT, Parson W, Meyers DJ, Cole PA, Culig Z (2011) Inhibition of the acetyltransferases p300 and CBP reveals a targetable function for p300 in the survival and invasion pathways of prostate cancer cell lines. Mol Cancer Ther 10(9):1644\u20131655. doi:10.1158\/1535-7163.MCT-11-0182","journal-title":"Mol Cancer Ther"},{"issue":"2","key":"239_CR141","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/0304-3835(85)90159-4","volume":"29","author":"R Kuttan","year":"1985","unstructured":"Kuttan R, Bhanumathy P, Nirmala K, George MC (1985) Potential anticancer activity of turmeric (Curcuma longa). Cancer Lett 29(2):197\u2013202","journal-title":"Cancer Lett"},{"issue":"5","key":"239_CR142","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1158\/0008-5472.CAN-11-0943","volume":"72","author":"S Shah","year":"2012","unstructured":"Shah S, Prasad S, Knudsen KE (2012) Targeting pioneering factor and hormone receptor cooperative pathways to suppress tumor progression. Cancer Res 72(5):1248\u20131259. doi:10.1158\/0008-5472.CAN-11-0943","journal-title":"Cancer Res"},{"issue":"25","key":"239_CR143","doi-asserted-by":"publisher","first-page":"17599","DOI":"10.1074\/jbc.274.25.17599","volume":"274","author":"ME Brady","year":"1999","unstructured":"Brady ME, Ozanne DM, Gaughan L, Waite I, Cook S, Neal DE, Robson CN (1999) Tip60 is a nuclear hormone receptor coactivator. J Biol Chem 274(25):17599\u201317604","journal-title":"J Biol Chem"},{"issue":"29","key":"239_CR144","doi-asserted-by":"publisher","first-page":"25904","DOI":"10.1074\/jbc.M203423200","volume":"277","author":"L Gaughan","year":"2002","unstructured":"Gaughan L, Logan IR, Cook S, Neal DE, Robson CN (2002) Tip60 and histone deacetylase 1 regulate androgen receptor activity through changes to the acetylation status of the receptor. J Biol Chem 277(29):25904\u201325913. doi:10.1074\/jbc.M203423200","journal-title":"J Biol Chem"},{"issue":"4","key":"239_CR145","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1016\/S0092-8674(00)00051-9","volume":"102","author":"T Ikura","year":"2000","unstructured":"Ikura T, Ogryzko VV, Grigoriev M, Groisman R, Wang J, Horikoshi M, Scully R, Qin J, Nakatani Y (2000) Involvement of the TIP60 histone acetylase complex in DNA repair and apoptosis. Cell 102(4):463\u2013473","journal-title":"Cell"},{"issue":"37","key":"239_CR146","doi-asserted-by":"publisher","first-page":"13182","DOI":"10.1073\/pnas.0504211102","volume":"102","author":"Y Sun","year":"2005","unstructured":"Sun Y, Jiang X, Chen S, Fernandes N, Price BD (2005) A role for the Tip60 histone acetyltransferase in the acetylation and activation of ATM. Proc Natl Acad Sci 102(37):13182\u201313187. doi:10.1073\/pnas.0504211102","journal-title":"Proc Natl Acad Sci"},{"issue":"16","key":"239_CR147","doi-asserted-by":"publisher","first-page":"2466","DOI":"10.1038\/sj.onc.1206342","volume":"22","author":"K Halkidou","year":"2003","unstructured":"Halkidou K, Gnanapragasam VJ, Mehta PB, Logan IR, Brady ME, Cook S, Leung HY, Neal DE, Robson CN (2003) Expression of Tip60, an androgen receptor coactivator, and its role in prostate cancer development. Oncogene 22(16):2466\u20132477. doi:10.1038\/sj.onc.1206342","journal-title":"Oncogene"},{"issue":"10","key":"239_CR148","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0045539","volume":"7","author":"K Coffey","year":"2012","unstructured":"Coffey K, Blackburn TJ, Cook S, Golding BT, Griffin RJ, Hardcastle IR, Hewitt L, Huberman K, McNeill HV, Newell DR, Roche C, Ryan-Munden CA, Watson A, Robson CN (2012) Characterisation of a Tip60 specific inhibitor, NU9056, in prostate cancer. PLoS ONE 7(10), e45539. doi:10.1371\/journal.pone.0045539","journal-title":"PLoS ONE"},{"key":"239_CR149","doi-asserted-by":"publisher","first-page":"5372","DOI":"10.1038\/srep05372","volume":"4","author":"C Gao","year":"2014","unstructured":"Gao C, Bourke E, Scobie M, Famme MA, Koolmeister T, Helleday T, Eriksson LA, Lowndes NF, Brown JAL (2014) Rational design and validation of a Tip60 histone acetyltransferase inhibitor. Sci Rep 4:5372. doi:10.1038\/srep05372","journal-title":"Sci Rep"},{"issue":"6683","key":"239_CR150","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1038\/30764","volume":"393","author":"X Nan","year":"1998","unstructured":"Nan X, Ng HH, Johnson CA, Laherty CD, Turner BM, Eisenman RN, Bird A (1998) Transcriptional repression by the methyl-CpG-binding protein MeCP2 involves a histone deacetylase complex. Nature 393(6683):386\u2013389. doi:10.1038\/30764","journal-title":"Nature"},{"issue":"2","key":"239_CR151","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1038\/561","volume":"19","author":"PL Jones","year":"1998","unstructured":"Jones PL, Veenstra GJ, Wade PA, Vermaak D, Kass SU, Landsberger N, Strouboulis J, Wolffe AP (1998) Methylated DNA and MeCP2 recruit histone deacetylase to repress transcription. Nat Genet 19(2):187\u2013191. doi:10.1038\/561","journal-title":"Nat Genet"},{"issue":"10","key":"239_CR152","doi-asserted-by":"publisher","first-page":"3373","DOI":"10.1128\/MCB.22.10.3373-3388.2002","volume":"22","author":"M Fu","year":"2002","unstructured":"Fu M, Wang C, Wang J, Zhang X, Sakamaki T, Yeung YG, Chang C, Hopp T, Fuqua SAW, Jaffray E, Hay RT, Palvimo JJ, JAnne OA, Pestell RG (2002) Androgen receptor acetylation governs trans activation and MEKK1-induced apoptosis without affecting in vitro sumoylation and trans-repression function. Mol Cell Biol 22(10):3373\u20133388","journal-title":"Mol Cell Biol"},{"issue":"3","key":"239_CR153","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1189\/jlb.0603289","volume":"75","author":"F Hayakawa","year":"2004","unstructured":"Hayakawa F, Towatari M, Ozawa Y, Tomita A, Privalsky ML, Saito H (2004) Functional regulation of GATA-2 by acetylation. J Leukoc Biol 75(3):529\u2013540. doi:10.1189\/jlb.0603389","journal-title":"J Leukoc Biol"},{"key":"239_CR154","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.gene.2005.09.010","volume":"363","author":"MA Glozak","year":"2005","unstructured":"Glozak MA, Sengupta N, Zhang X, Seto E (2005) Acetylation and deacetylation of non-histone proteins. Gene 363:15\u201323. doi:10.1016\/j.gene.2005.09.010","journal-title":"Gene"},{"issue":"5","key":"239_CR155","doi-asserted-by":"publisher","first-page":"1241","DOI":"10.1073\/pnas.0307708100","volume":"101","author":"C-Y Gui","year":"2004","unstructured":"Gui C-Y, Ngo L, Xu WS, Richon VM, Marks PA (2004) Histone deacetylase (HDAC) inhibitor activation of p21WAF1 involves changes in promoter-associated proteins, including HDAC1. Proc Natl Acad Sci 101(5):1241\u20131246. doi:10.1073\/pnas.0307708100","journal-title":"Proc Natl Acad Sci"},{"issue":"19","key":"239_CR156","doi-asserted-by":"publisher","first-page":"13548","DOI":"10.1074\/jbc.M510023200","volume":"281","author":"AJ Wilson","year":"2006","unstructured":"Wilson AJ, Byun D-S, Popova N, Murray LB, L\u2019Italien K, Sowa Y, Arango D, Velcich A, Augenlicht LH, Mariadason JM (2006) Histone deacetylase 3 (HDAC3) and other class I HDACs regulate colon cell maturation and p21 expression and are deregulated in human colon cancer. J Biol Chem 281(19):13548\u201313558. doi:10.1074\/jbc.M510023200","journal-title":"J Biol Chem"},{"issue":"3","key":"239_CR157","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1038\/sj.bjc.6604199","volume":"98","author":"W Weichert","year":"2008","unstructured":"Weichert W, R\u00f6ske A, Gekeler V, Beckers T, Stephan C, Jung K, Fritzsche FR, Niesporek S, Denkert C, Dietel M, Kristiansen G (2008) Histone deacetylases 1, 2 and 3 are highly expressed in prostate cancer and HDAC2 expression is associated with shorter PSA relapse time after radical prostatectomy. Br J Cancer 98(3):604\u2013610. doi:10.1038\/sj.bjc.6604199","journal-title":"Br J Cancer"},{"issue":"23","key":"239_CR158","doi-asserted-by":"publisher","first-page":"8563","DOI":"10.1128\/MCB.23.23.8563-8575.2003","volume":"23","author":"M Fu","year":"2003","unstructured":"Fu M, Rao M, Wang C, Sakamaki T, Wang J, Di Vizio D, Zhang X, Albanese C, Balk S, Chang C, Fan S, Rosen E, Palvimo JJ, JAnne OA, Muratoglu S, Avantaggiati ML, Pestell RG (2003) Acetylation of androgen receptor enhances coactivator binding and promotes prostate cancer cell growth. Mol Cell Biol 23(23):8563\u20138575","journal-title":"Mol Cell Biol"},{"issue":"3","key":"239_CR159","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1158\/0008-5472.CAN-08-2216","volume":"69","author":"DS Welsbie","year":"2009","unstructured":"Welsbie DS, Xu J, Chen Y, Borsu L, Scher HI, Rosen N, Sawyers CL (2009) Histone deacetylases are required for androgen receptor function in hormone-sensitive and castrate-resistant prostate cancer. Cancer Res 69(3):958\u2013966. doi:10.1158\/0008-5472.CAN-08-2216","journal-title":"Cancer Res"},{"issue":"8","key":"239_CR160","doi-asserted-by":"publisher","first-page":"1807","DOI":"10.1210\/me.2006-0467","volume":"21","author":"Y Dai","year":"2007","unstructured":"Dai Y, Ngo D, Forman LW, Qin DC, Jacob J, Faller DV (2007) Sirtuin 1 is required for antagonist-induced transcriptional repression of androgen-responsive genes by the androgen receptor. Mol Endocrinol 21(8):1807\u20131821. doi:10.1210\/me.2006-0467","journal-title":"Mol Endocrinol"},{"key":"239_CR161","doi-asserted-by":"publisher","DOI":"10.1038\/cddis.2013.9","volume":"4","author":"JE Bolden","year":"2013","unstructured":"Bolden JE, Shi W, Jankowski K, Kan C-Y, Cluse L, Martin BP, MacKenzie KL, Smyth GK, Johnstone RW (2013) HDAC inhibitors induce tumor-cell-selective pro-apoptotic transcriptional responses. Cell Death Dis 4, e519. doi:10.1038\/cddis.2013.9","journal-title":"Cell Death Dis"},{"issue":"6","key":"239_CR162","doi-asserted-by":"publisher","first-page":"300","DOI":"10.4161\/epi.3.6.7273","volume":"3","author":"A Abbas","year":"2008","unstructured":"Abbas A, Gupta S (2008) The role of histone deacetylases in prostate cancer. Epigenetics 3(6):300\u2013309","journal-title":"Epigenetics"},{"issue":"10","key":"239_CR163","doi-asserted-by":"publisher","first-page":"1247","DOI":"10.1634\/theoncologist.12-10-1247","volume":"12","author":"BS Mann","year":"2007","unstructured":"Mann BS, Johnson JR, Cohen MH, Justice R, Pazdur R (2007) FDA approval summary: vorinostat for treatment of advanced primary cutaneous T-cell lymphoma. Oncologist 12(10):1247\u20131252. doi:10.1634\/theoncologist.12-10-1247","journal-title":"Oncologist"},{"issue":"32","key":"239_CR164","doi-asserted-by":"publisher","first-page":"5410","DOI":"10.1200\/JCO.2008.21.6150","volume":"27","author":"RL Piekarz","year":"2009","unstructured":"Piekarz RL, Frye R, Turner M, Wright JJ, Allen SL, Kirschbaum MH, Zain J, Prince HM, Leonard JP, Geskin LJ, Reeder C, Joske D, Figg WD, Gardner ER, Steinberg SM, Jaffe ES, Stetler-Stevenson M, Lade S, Fojo AT, Bates SE (2009) Phase II multi-institutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T-cell lymphoma. J Clin Oncol 27(32):5410\u20135417. doi:10.1200\/JCO.2008.21.6150","journal-title":"J Clin Oncol"},{"key":"239_CR165","doi-asserted-by":"crossref","unstructured":"Fenichel MP (2015) FDA approves new agent for multiple myeloma. J Natl Cancer Inst. djv165","DOI":"10.1093\/jnci\/djv165"},{"key":"239_CR166","doi-asserted-by":"publisher","first-page":"S2","DOI":"10.1038\/sj.bjc.6603463","volume":"95","author":"VM Richon","year":"2006","unstructured":"Richon VM (2006) Cancer biology: mechanism of antitumour action of vorinostat (suberoylanilide hydroxamic acid), a novel histone deacetylase inhibitor. Br J Cancer 95:S2\u2013S6. doi:10.1038\/sj.bjc.6603463","journal-title":"Br J Cancer"},{"issue":"23","key":"239_CR167","doi-asserted-by":"publisher","first-page":"5541","DOI":"10.1002\/cncr.24597","volume":"115","author":"D Bradley","year":"2009","unstructured":"Bradley D, Rathkopf D, Dunn R, Stadler WM, Liu G, Smith DC, Pili R, Zwiebel J, Scher H, Hussain M (2009) Vorinostat in advanced prostate cancer patients progressing on prior chemotherapy (National Cancer Institute Trial 6862): trial results and interleukin-6 analysis: a study by the Department of Defense Prostate Cancer Clinical Trial Consortium and University of Chicago Phase 2 Consortium. Cancer 115(23):5541\u20135549. doi:10.1002\/cncr.24597","journal-title":"Cancer"},{"issue":"13","key":"239_CR168","doi-asserted-by":"publisher","first-page":"4694","DOI":"10.1021\/jm2003552","volume":"54","author":"H Wang","year":"2011","unstructured":"Wang H, Yu N, Chen D, Lee KCL, Lye PL, Chang JWW, Deng W, Ng MCY, Lu T, Khoo ML, Poulsen A, Sangthongpitag K, Wu X, Hu C, Goh KC, Wang X, Fang L, Goh KL, Khng HH, Goh SK, Yeo P, Liu X, Bonday Z, Wood JM, Dymock BW, Kantharaj E, Sun ET (2011) Discovery of (2E)-3-{2-butyl-1-[2-(diethylamino)ethyl]-1H-benzimidazol-5-yl}-N-hydroxyacrylamide (SB939), an orally active histone deacetylase inhibitor with a superior preclinical profile. J Med Chem 54(13):4694\u20134720. doi:10.1021\/jm2003552","journal-title":"J Med Chem"},{"issue":"4","key":"239_CR169","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1007\/s10637-015-0252-4","volume":"33","author":"BJ Eigl","year":"2015","unstructured":"Eigl BJ, North S, Winquist E, Finch D, Wood L, Sridhar SS, Powers J, Good J, Sharma M, Squire JA, Bazov J, Jamaspishvili T, Cox ME, Bradbury PA, Eisenhauer EA, Chi KN (2015) A phase II study of the HDAC inhibitor SB939 in patients with castration resistant prostate cancer: NCIC clinical trials group study IND195. Invest New Drugs 33(4):969\u2013976. doi:10.1007\/s10637-015-0252-4","journal-title":"Invest New Drugs"},{"issue":"9","key":"239_CR170","doi-asserted-by":"publisher","first-page":"2751","DOI":"10.3390\/ph3092751","volume":"3","author":"S Subramanian","year":"2010","unstructured":"Subramanian S, Bates SE, Wright JJ, Espinoza-Delgado I, Piekarz RL (2010) Clinical toxicities of histone deacetylase inhibitors. Pharmaceuticals 3(9):2751\u20132767. doi:10.3390\/ph3092751","journal-title":"Pharmaceuticals"},{"issue":"1","key":"239_CR171","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1007\/s10637-010-9503-6","volume":"30","author":"BJ Schneider","year":"2012","unstructured":"Schneider BJ, Kalemkerian GP, Bradley D, Smith DC, Egorin MJ, Daignault S, Dunn R, Hussain M (2012) Phase I study of vorinostat (suberoylanilide hydroxamic acid, NSC 701852) in combination with docetaxel in patients with advanced and relapsed solid malignancies. Invest New Drugs 30(1):249\u2013257. doi:10.1007\/s10637-010-9503-6","journal-title":"Invest New Drugs"},{"issue":"1","key":"239_CR172","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1093\/annonc\/mdp270","volume":"21","author":"LR Molife","year":"2010","unstructured":"Molife LR, Attard G, Fong PC, Karavasilis V, Reid AHM, Patterson S, Riggs CE, Higano C, Stadler WM, McCulloch W, Dearnaley D, Parker C, de Bono JS (2010) Phase II, two-stage, single-arm trial of the histone deacetylase inhibitor (HDACi) romidepsin in metastatic castration-resistant prostate cancer (CRPC). Ann Oncol 21(1):109\u2013113. doi:10.1093\/annonc\/mdp270","journal-title":"Ann Oncol"},{"issue":"12","key":"239_CR173","doi-asserted-by":"publisher","first-page":"1828","DOI":"10.1038\/bjc.2011.156","volume":"104","author":"PN Munster","year":"2011","unstructured":"Munster PN, Thurn KT, Thomas S, Raha P, Lacevic M, Miller A, Melisko M, Ismail-Khan R, Rugo H, Moasser M, Minton SE (2011) A phase II study of the histone deacetylase inhibitor vorinostat combined with tamoxifen for the treatment of patients with hormone therapy-resistant breast cancer. Br J Cancer 104(12):1828\u20131835. doi:10.1038\/bjc.2011.156","journal-title":"Br J Cancer"},{"issue":"11","key":"239_CR174","doi-asserted-by":"publisher","first-page":"5517","DOI":"10.1073\/pnas.93.11.5517","volume":"93","author":"S Yeh","year":"1996","unstructured":"Yeh S, Chang C (1996) Cloning and characterization of a specific coactivator, ARA70, for the androgen receptor in human prostate cells. Proc Natl Acad Sci 93(11):5517\u20135521","journal-title":"Proc Natl Acad Sci"},{"issue":"1","key":"239_CR175","doi-asserted-by":"publisher","first-page":"225","DOI":"10.2353\/ajpath.2008.070065","volume":"172","author":"Y Peng","year":"2008","unstructured":"Peng Y, Li CX, Chen F, Wang Z, Ligr M, Melamed J, Wei J, Gerald W, Pagano M, Garabedian MJ, Lee P (2008) Stimulation of prostate cancer cellular proliferation and invasion by the androgen receptor co-activator ARA70. Am J Pathol 172(1):225\u2013235. doi:10.2353\/ajpath.2008.070065","journal-title":"Am J Pathol"},{"issue":"9","key":"239_CR176","doi-asserted-by":"publisher","first-page":"3046","DOI":"10.1158\/0008-5472.CAN-03-2614","volume":"64","author":"C Jung","year":"2004","unstructured":"Jung C, Kim R-S, Lee S-J, Wang C, Jeng M-H (2004) HOXB13 homeodomain protein suppresses the growth of prostate cancer cells by the negative regulation of T-cell factor 4. Cancer Res 64(9):3046\u20133051","journal-title":"Cancer Res"},{"issue":"3","key":"239_CR177","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1016\/j.molcel.2009.10.020","volume":"36","author":"JD Norris","year":"2009","unstructured":"Norris JD, Chang C-Y, Wittmann BM, Kunder RS, Cui H, Fan D, Joseph JD, McDonnell DP (2009) The homeodomain protein HOXB13 regulates the cellular response to androgens. Mol Cell 36(3):405\u2013416. doi:10.1016\/j.molcel.2009.10.020","journal-title":"Mol Cell"},{"issue":"2","key":"239_CR178","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1056\/NEJMoa1110000","volume":"366","author":"CM Ewing","year":"2012","unstructured":"Ewing CM, Ray AM, Lange EM, Zuhlke KA, Robbins CM, Tembe WD, Wiley KE, Isaacs SD, Johng D, Wang Y, Bizon C, Yan G, Gielzak M, Partin AW, Shanmugam V, Izatt T, Sinari S, Craig DW, Zheng SL, Walsh PC, Montie JE, Xu J, Carpten JD, Isaacs WB, Cooney KA (2012) Germline mutations in HOXB13 and prostate-cancer risk. N Engl J Med 366(2):141\u2013149. doi:10.1056\/NEJMoa1110000","journal-title":"N Engl J Med"},{"issue":"3","key":"239_CR179","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1002\/(SICI)1097-0045(19991101)41:3<203::AID-PROS8>3.0.CO;2-J","volume":"41","author":"T Sreenath","year":"1999","unstructured":"Sreenath T, Orosz A, Fujita K, Bieberich CJ (1999) Androgen-independent expression of hoxb-13 in the mouse prostate. Prostate 41(3):203\u2013207","journal-title":"Prostate"},{"issue":"10","key":"239_CR180","doi-asserted-by":"publisher","first-page":"2061","DOI":"10.1242\/dev.00432","volume":"130","author":"KD Economides","year":"2003","unstructured":"Economides KD, Capecchi MR (2003) Hoxb13 is required for normal differentiation and secretory function of the ventral prostate. Development 130(10):2061\u20132069","journal-title":"Development"},{"key":"239_CR181","doi-asserted-by":"publisher","DOI":"10.1038\/ng.3419","author":"MM Pomerantz","year":"2015","unstructured":"Pomerantz MM, Li F, Takeda DY, Lenci R, Chonkar A, Chabot M, Cejas P, Vazquez F, Cook J, Shivdasani RA, Bowden M, Lis R, Hahn WC, Kantoff PW, Brown M, Loda M, Long HW, Freedman ML (2015) The androgen receptor cistrome is extensively reprogrammed in human prostate tumorigenesis. Nat Publ Group. doi:10.1038\/ng.3419","journal-title":"Nat Publ Group"},{"issue":"1","key":"239_CR182","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1073\/pnas.0902001107","volume":"107","author":"RP McMullin","year":"2010","unstructured":"McMullin RP, Dobi A, Mutton LN, Orosz A, Maheshwari S, Shashikant CS, Bieberich CJ (2010) A FOXA1-binding enhancer regulates Hoxb13 expression in the prostate gland. Proc Natl Acad Sci U S A 107(1):98\u2013103. doi:10.1073\/pnas.0902001107","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"5","key":"239_CR183","doi-asserted-by":"publisher","first-page":"1956","DOI":"10.1158\/0008-5472.CAN-10-2421","volume":"71","author":"P \u00d6stling","year":"2011","unstructured":"\u00d6stling P, Leivonen S-K, Aakula A, Kohonen P, M\u00e4kel\u00e4 R, Hagman Z, Edsj\u00f6 A, Kangaspeska S, Edgren H, Nicorici D, Bjartell A, Ceder Y, Per\u00e4l\u00e4 M, Kallioniemi O (2011) Systematic analysis of microRNAs targeting the androgen receptor in prostate cancer cells. Cancer Res 71(5):1956\u20131967. doi:10.1158\/0008-5472.CAN-10-2421","journal-title":"Cancer Res"},{"key":"239_CR184","doi-asserted-by":"publisher","DOI":"10.1038\/onc.2015.295","author":"C Coarfa","year":"2015","unstructured":"Coarfa C, Fiskus W, Eedunuri VK, Rajapakshe K, Foley C, Chew SA, Shah SS, Geng C, Shou J, Mohamed JS, O\u2019Malley BW, Mitsiades N (2015) Comprehensive proteomic profiling identifies the androgen receptor axis and other signaling pathways as targets of microRNAs suppressed in metastatic prostate cancer. Oncogene. doi:10.1038\/onc.2015.295","journal-title":"Oncogene"},{"issue":"3","key":"239_CR185","doi-asserted-by":"publisher","first-page":"1232","DOI":"10.1158\/0008-5472.CAN-12-2968","volume":"73","author":"P-C Lin","year":"2013","unstructured":"Lin P-C, Chiu Y-L, Banerjee S, Park K, Mosquera J-M, Giannopoulou E, Alves P, Tewari AK, Gerstein MB, Beltran H, Melnick AM, Elemento O, Demichelis F, Rubin MA (2013) Epigenetic repression of miR-31 disrupts androgen receptor homeostasis and contributes to prostate cancer progression. Cancer Res 73(3):1232\u20131244. doi:10.1158\/0008-5472.CAN-12-2968","journal-title":"Cancer Res"},{"issue":"1","key":"239_CR186","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.clgc.2014.07.008","volume":"13","author":"R Singal","year":"2015","unstructured":"Singal R, Ramachandran K, Gordian E, Quintero C, Zhao W, Reis IM (2015) Phase I\/II study of azacitidine, docetaxel, and prednisone in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel-based therapy. Clin Genitourin Cancer 13(1):22\u201331. doi:10.1016\/j.clgc.2014.07.008","journal-title":"Clin Genitourin Cancer"}],"container-title":["Hormones and Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-015-0239-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12672-015-0239-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-015-0239-9","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-015-0239-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,12,29]],"date-time":"2020-12-29T17:49:35Z","timestamp":1609264175000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12672-015-0239-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,1,4]]},"references-count":186,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2016,4]]}},"alternative-id":["239"],"URL":"https:\/\/doi.org\/10.1007\/s12672-015-0239-9","relation":{},"ISSN":["1868-8497","1868-8500"],"issn-type":[{"value":"1868-8497","type":"print"},{"value":"1868-8500","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,1,4]]},"assertion":[{"value":"3 September 2015","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 November 2015","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 January 2016","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"All authors state that they have no relevant financial interests to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This work was also supported by the American Cancer Society RSG-14-218-01-TBG (to N.M.), the Prostate Cancer Foundation (N.M.), the Conquer Cancer Foundation of the American Society of Clinical Oncology Young Investigator and Career Development Awards (both to N.M.), and the Pilot\/Feasibility Program of the Diabetes & Endocrinology Research Center (P30-DK079638) at Baylor College of Medicine (N.M.). N.M. is supported by NCI grant 1R01CA193321, is a Dan L. Duncan Scholar, a Caroline Wiess Law Scholar, and member of the Dan L. Duncan Cancer Center (supported by the NCI Cancer Center Support Grant P30CA125123).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding\/Support"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}